Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Short-term Investments (2023 - 2025)

Historic Short-term Investments for Immunome (IMNM) over the last 3 years, with Q2 2025 value amounting to $124.2 million.

  • Immunome's Short-term Investments rose 989.11% to $124.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $124.2 million, marking a year-over-year increase of 989.11%. This contributed to the annual value of $74.0 million for FY2024, which is 8739.58% up from last year.
  • As of Q2 2025, Immunome's Short-term Investments stood at $124.2 million, which was up 989.11% from $59.7 million recorded in Q1 2025.
  • Over the past 5 years, Immunome's Short-term Investments peaked at $124.2 million during Q2 2025, and registered a low of $39.5 million during Q4 2023.
  • Moreover, its 3-year median value for Short-term Investments was $74.0 million (2024), whereas its average is $76.4 million.
  • In the last 5 years, Immunome's Short-term Investments soared by 8739.58% in 2024 and then surged by 989.11% in 2025.
  • Immunome's Short-term Investments (Quarter) stood at $39.5 million in 2023, then surged by 87.4% to $74.0 million in 2024, then soared by 67.95% to $124.2 million in 2025.
  • Its Short-term Investments was $124.2 million in Q2 2025, compared to $59.7 million in Q1 2025 and $74.0 million in Q4 2024.